What is the recommended duloxetine dosing regimen, including starting dose, titration schedule, maximum dose, and adjustments for hepatic or renal impairment and elderly patients?

Duloxetine Dosing

Start duloxetine at 30 mg once daily for 1 week, then increase to the target dose of 60 mg once daily, with a maximum dose of 120 mg daily (given as 60 mg twice daily) if needed, though doses above 60 mg rarely provide additional benefit. 1

Standard Dosing Regimen

Starting Dose

• 30 mg once daily for the first week to minimize nausea and improve tolerability 2, 1
• Taking the medication with food significantly reduces nausea, particularly when starting at higher doses 3

Target Dose

• 60 mg once daily is the therapeutic dose for most indications 1
• This dose is as effective as 60 mg twice daily for neuropathic pain and depression 2
• An adequate trial requires 4 weeks at the target dose 2

Maximum Dose

• 120 mg daily (60 mg twice daily) is the maximum studied dose 1
• Important caveat: Doses above 60 mg/day provide no additional benefit for most conditions and significantly increase adverse effects 1
• For diabetic neuropathic pain specifically, doses higher than 60 mg are "clearly less well tolerated" without added efficacy 1

Special Population Adjustments

Elderly Patients (≥65 years)

• Start at 30 mg once daily for 2 weeks before increasing to 60 mg 1
• Use slower titration compared to younger adults 2
• The 30 mg starting dose for 2 weeks is particularly important as elderly patients showed good tolerability at this regimen 4
• Maximum dose remains 120 mg daily, though many elderly patients respond to lower doses 5

Hepatic Impairment

• Avoid use entirely in patients with chronic liver disease or cirrhosis 1
• This is a firm contraindication, not just a dose reduction 1

Renal Impairment

• Mild to moderate impairment (CrCl ≥30 mL/min): No dose adjustment needed 6
• Severe impairment (CrCl <30 mL/min) or end-stage renal disease: Avoid use 1
• Duloxetine exposure increases 2-fold and metabolite exposure increases up to 9-fold in ESRD 6
• For diabetic patients (who commonly have renal disease), consider starting at a lower dose and titrate gradually 1

Titration Algorithm by Indication

Depression or Generalized Anxiety Disorder

1. Week 1: 30 mg once daily (with food preferred)
2. Week 2 onward: 60 mg once daily
3. If inadequate response after 4 weeks at 60 mg: May increase to 120 mg daily in 30 mg increments
4. Elderly: Extend the 30 mg phase to 2 weeks before advancing

Diabetic Neuropathic Pain

1. Start directly at 60 mg once daily 1
2. For tolerability concerns: Start at 30 mg daily for 1 week, then increase to 60 mg
3. Do not exceed 60 mg daily - higher doses offer no benefit and worse tolerability 1
4. Monitor blood glucose as duloxetine may worsen glycemic control 1

Fibromyalgia or Chronic Musculoskeletal Pain

1. Week 1: 30 mg once daily
2. Week 2 onward: 60 mg once daily
3. Do not exceed 60 mg daily - no evidence of additional benefit at higher doses 1

Critical Prescribing Considerations

Drug Interactions Requiring Dose Modification

• CYP1A2 inhibitors (especially fluvoxamine): Avoid combination or use lowest effective duloxetine dose - fluvoxamine increases duloxetine exposure by 460% 7
• Smoking: Decreases duloxetine concentrations by 30%; may need higher doses in smokers 7, 8
• CYP2D6 inhibitors: Modest increase in duloxetine exposure but no dose adjustment required 7

Discontinuation

• Taper gradually rather than stopping abruptly to minimize withdrawal symptoms (dizziness, nausea, headache, paresthesia) 1
• Allow at least 5 days after stopping duloxetine before starting an MAOI 1

Common Pitfalls to Avoid

• Do not crush or open capsules - this destroys the enteric coating needed to prevent premature drug release 1
• Do not start at 60 mg without food in tolerability-sensitive patients - this maximizes nausea risk 3
• Do not exceed 60 mg for pain conditions - this is a common error that increases side effects without improving outcomes 1
• Do not use in patients with gastroparesis or delayed gastric emptying - the enteric coating stability depends on normal GI motility 1